Vascular Biogenics (VBLT) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Vascular Biogenics (NASDAQ:VBLT) from a sell rating to a hold rating in a research note released on Saturday, January 6th.

According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “

A number of other equities analysts have also recently weighed in on the company. HC Wainwright reissued a buy rating and issued a $11.00 price target on shares of Vascular Biogenics in a research note on Tuesday, November 21st. Chardan Capital lifted their price target on Vascular Biogenics from $20.00 to $25.00 and gave the stock a buy rating in a research note on Monday, November 6th. Finally, ValuEngine cut Vascular Biogenics from a hold rating to a sell rating in a research note on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Vascular Biogenics has a consensus rating of Hold and an average price target of $15.67.

Shares of Vascular Biogenics (NASDAQ VBLT) opened at $7.75 on Friday. Vascular Biogenics has a 1 year low of $3.90 and a 1 year high of $9.05. The company has a market cap of $234.91, a PE ratio of -9.81 and a beta of -3.00.

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). sell-side analysts expect that Vascular Biogenics will post -0.9 EPS for the current fiscal year.

An institutional investor recently bought a new position in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Vascular Biogenics Ltd (NASDAQ:VBLT) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.08% of Vascular Biogenics at the end of the most recent quarter. 6.59% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.

Leave a Reply